Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin presented as an injection solution for subcutaneous administration. It provides exogenous follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity to stimulate ovarian follicular development and ovulation in women with infertility due to anovulation or undergoing assisted reproductive technology cycles.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this fertility therapy for qualified healthcare providers and patients through established distribution networks.

Menopur (menotropin) is used in fertility treatment to stimulate ovarian function. - Infertility due to anovulation: promotes follicular growth and ovulation to improve chances of conception. - Controlled ovarian stimulation in assisted reproductive technology (ART): supports multiple follicle development for IVF or ICSI cycles. - Ovarian stimulation for egg donation programs: enhances oocyte yield in donor cycles. - Luteal phase support in certain protocols: provides LH activity to aid corpus luteum function.

Menopur may cause a range of adverse reactions, which are generally related to its hormonal activity and injection site. Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Abdominal bloating: transient abdominal distension. - Nausea: occasional nausea. Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, abdominal pain, shortness of breath. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reaction: rash, urticaria, or anaphylaxis.

Before using Menopur, consider the following precautions to minimize risks and ensure safe administration. - Assess ovarian reserve: evaluate baseline follicle count and hormone levels before initiating therapy. - Monitor for OHSS: regular ultrasound and estradiol monitoring to detect early signs of ovarian hyperstimulation syndrome. - Review medical history: contraindicate use in active malignancy, uncontrolled thyroid disease, or severe cardiovascular conditions. - Avoid concurrent gonadotropins: do not combine with other FSH or LH preparations without specialist guidance. - Pregnancy testing: confirm negative pregnancy test prior to starting treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Menopur can interact with other medicines or hormonal agents; awareness of these interactions helps prevent adverse outcomes. Major Interactions (Avoid): - GnRH antagonists: may blunt the intended ovarian response. - High‑dose estrogen therapy: can interfere with follicular development. - Anticoagulants: increased risk of bleeding from ovarian cyst rupture. Moderate Interactions (Monitor Closely): - Oral contraceptives: may require washout period before stimulation. - Thyroid hormone replacement: monitor thyroid function as gonadotropins can affect hormone levels. - Diuretics: may mask fluid shifts associated with OHSS.